SCHEMBL30009357

SCHEMBL30009357

CC1C=CCN(C(=O)c2cc(Cl)ncc2Cl)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
HPGD P15428 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
LRRK2 Q5S007 4/20 0.32
GRM4 Q14833 1/20 0.31
WNK1 Q9H4A3 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSP90AA1 P07900 1/20 0.31
TLR2 O60603 1/20 0.31
TLR1 Q15399 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
CHRM4 P08173 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009435 0.78 PROKR1 (0.49)
SCHEMBL30009886 0.76 JAK1 (0.39) HPGDSMN1; SMN2ALDH1A1LMNACYP3A4
SCHEMBL30009910 0.76 JAK1 (0.40) ALDH1A1HRH4
SCHEMBL30008761 0.75 AKR1C4 (0.43) TSHRHPGDSMN1; SMN2ALDH1A1LMNA
SCHEMBL30009239 0.74 P2RX7 (0.51) TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL30008788 0.73 PROKR1 (0.44) ALDH1A1
SCHEMBL30009582 0.70 GAA (0.38) TSHRHPGDALDH1A1HSP90AA1HRH4
SCHEMBL30009295 0.69 JAK1 (0.43) TSHRHPGDSMN1; SMN2ALDH1A1
SCHEMBL504856 0.65 TFPI2 (0.30)
SCHEMBL30567639 0.65 MAPK1 (0.40) TSHRHPGDSMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 TSHR 2716/4885HPGD 2910/4885SMN1; SMN2 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.